Introduction: Primary adenocarcinoma of the bladder is a very rare disease that is difficult to treat. In this paper, we report the second case in the literature with primary mucinous adenocarcinoma of the bladder which showed complete response to FOLFOX4 (fluorouracil, leucovorin, oxaliplatin) chemotherapy regimen. Case Report: A 41-year-old man was admitted to our hospital with a diagnosis of primary adenocarcinoma of the bladder. Due to the similarity in histology with colon carcinoma, a FOLFOX4 regimen was started. Complete response was achieved at the end of this treatment. Today the patient is free of local or systemic disease. Conclusion: FOLFOX4 regimen may be a treatment option for primary adenocarcinoma of the bladder.

Keywords:
Bladder cancer, Mucinous adenocarcinoma, Chemotherapy, FOLFOX4
1.
Lynch CF, Cohen MB: Urinary system. Cancer 1995;75(1 suppl):316-329.
2.
Tatli AM, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, Coskun HS, Bozcuk H, Savas B: Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen. Med Oncol 2012;29:1935-1937.
3.
Zaghloul MS, Nouh A, Nazmy M, Ramzy S, Zaghloul AS, Sedira MA, Khalil E: Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 2006;24:13-20.
4.
Valerio M, Lhermitte B, Bauer J, Jichlinski P: Metastatic primary adenocarcinoma of the bladder in a twenty-five years old woman. Rare Tumors 2011;3:e9.
5.
Teo MY, Swan NC, McDermott RS: Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab. Nat Rev Urol 2011;8:282-285.
6.
Singh J, Zherebitskiy V, Grynspan D, Czaykowski PM: Metastatic signet ring cell adenocarcinoma of the bladder: responsive to treatment? Can Urol Assoc J 2012;6:E15-E19.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.